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January 2001 for CML at our institution were retrospectively
reviewed. Imatinib-refractory CML was deﬁned as either lack of
any cytogenetic response (CGR) after at least 6mths of imatinib,
loss of CGR or progression to a more advanced disease stage
(accelerated or blast phase) during imatinib therapy. Using the
EBMT risk score (Lancet 1998; 352: 1087), transplant outcomes
for imatinib refractory CML were compared with all other CML
transplants performed during the same time period. Survival anal-
ysis was performed using the Kaplan-Meier product-limit and
comparison of survival data via the log-rank test.
Results: Of 31 allogeneic transplants (19M; 12F) performed for
CML, 12 had been performed for imatinib refractory CML (no
CGR to imatinib n3; loss of CGR n3; progression to AP n3;
progression to BC n3), 5 in patients with imatinib responsive
CML, and 14 in patients never exposed to imatinib. Median age at
SCT was 40yrs (range 19-63yrs). Donor source included HLA-
matched unrelated donors in 14 cases, HLA-identical siblings in 16
and other matched family donors in 1. Graft source consisted of
PBSC (17), BM (8) and G-BM (6). Conditioning regimens in-
cluded Cy/TBI (20 cases), Bu/Cy (8 cases), Flu/Mel (2 cases) and
Flu/Cy (1 case). CsA  MTX was used as standard GVHD pro-
phylaxis (29), CsA alone (1) and Tacrolimus/Mycophenolate (1).
EBMT risk scores were 1 (4 cases), 2 (6 cases), 3 (8 cases), 4 (5
cases), 5 (3 cases) and 6 (5 cases). At median follow-up post-SCT of
37mths (range 6-64mths), median PFS and OS are not reached; at
2yrs PFS, EFS and OS are 81%, 58% and 61% respectively. For
patients with EBMT risk scores of 1-2 versus 3-4 versus 5-6, OS at
2 yrs post-SCT is 80%, 62% and 38% respectively (p0.03). Based
on EBMT risk score, no signiﬁcant differences in PFS, EFS or OS
were observed when comparing SCT for imatinib-refractory versus
imatinib-responsive / imatinib-naive CML.
Conclusion: Our experience suggests that survival post-SCT for
imatinib-refractory CML is similar to SCT for imatinib-responsive
/ imatinib-naive CML. The EBMT risk score remains useful in
predicting survival post-SCT in imatinib-refractory CML.
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mTOR INHIBITORS (MTI) ARE SYNERGISTIC WITH METHOTREXATE:
AN EFFECTIVE COMBINATION TO BOTH PREVENT POST-HSCT RE-
LAPSE OF ALL AND PREVENT GVHD
Teachey, D.T.1, Brown, V.I.1, Fish, J.1, Reid, G.1, Grupp, S.A.1 1Chil-
dren’s Hospital, Philadelphia, PA.
Many adults and some children with ALL relapse and may
require HSCT for cure. We have previously demonstrated that
MTI, including sirolimus and its ester temsirolimus, are active
against primary human ALL in preclinical models. Recent data in
HSCT indicate efﬁcacy of sirolimus-based GVHD prophylaxis.
Thus, MTI have the potential to both control GVHD and elimi-
nate minimal residual ALL after HSCT. MTI downregulate cyclin
D1 which is involved in dihydrofolate reductase (DHFR) synthesis.
Sensitivity to methotrexate has been shown to correlate with
DHFR expression. Thus, MTI may increase sensitivity of ALL to
methotrexate through decreasing DHFR by increasing turnover of
cyclin D1. We hypothesized MTI and methotrexate would exhibit
synergy against human ALL, suggesting that this combination
could be used as an effective means to prevent both recurrence and
GVHD. We used the relevant preclinical model of NOD/SCID
mice xenografted with primary ALL patient samples. The MTI
sirolimus and temsirolimus signiﬁcantly decrease ALL in xe-
nografted mice with large disease burdens. To test possible syn-
ergy, after establishment of disease, mice were randomized to
treatment with control, temsirolimus (daily or weekly), methotrex-
ate (5mg/kg/weekly) or both drugs combined. Disease was evalu-
ated at weekly intervals by FACS of peripheral blood for CD19/
CD45 ALL cells. The combination of methotrexate and
temsirolimus demonstrated an additive and potentially synergistic
effect. Control mice died after 21 d. Mice treated with temsiroli-
mus or methotrexate alone had initial improvement in ALL fol-
lowed by progression after 4-5 weeks. Mice treated with both drugs
had a complete and durable resolution of peripheral blasts by d 21.
After d 42 treatment was stopped. Mice treated with both drugs
remained in remission and were disease free when sacriﬁced 2
months later in contrast to either single agent treatment group
which died of disease. Kaplan-Meyer analysis of time to progres-
sion demonstrated a statistically signiﬁcant difference, comparing
all treatment arms to control (p 0.01), and comparing the com-
bination of drugs to methotrexate only (p 0.03) and temsirolimus
only (p  0.07) in both samples.
Conclusion: We found methotrexate and MTI are an effective
and potentially synergistic combination in ALL. These agents
could be used to both treat ALL and prevent GVHD, making it an
ideal combination for use as GVHD prophylaxis for ALL patients
undergoing HSCT.
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NEIC REDUCED-INTENSITY PERIPHERAL BLOOD STEM CELL TRANS-
PLANTATION (SCT) FOR ADVANCED MYELODYSPLASTIC SYNDROME
(MDS) OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
Ho, V.T.1, Dranoff, G.1, Kim, H.1, Pasek, M.1, Cutler, C.1, Koreth, J.1,
Alyea, E.P.1, Antin, J.H.1, Soiffer, R.J.1 1Dana-Farber Cancer Insti-
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Disease relapse is a frequent cause of treatment failure in patients
undergoing reduced intensity allogeneic SCT for advanced MDS
and AML. Prior studies with GVAX, a cancer vaccine composed of
irradiated autologous myeloblasts modiﬁed to secrete GM-CSF,
suggested anticancer activity in MDS/AML after autologous SCT
or in primary therapy. We investigated the feasibility and safety of
administering GVAX after allogeneic SCT. Patients with MDS-
RAEB or AML with 5% marrow blasts and with a donor
matched at HLA-A,B, DRB1 were eligible. Prior to SCT, autol-
ogous myeloblasts were collected from the marrow or blood and
transfected with an adenovirus vector bearing the GM-CSF gene
to generate the GVAX vaccine. Conditioning consisted of ﬂudara-
bine 30mg/m2/d IV and busulfan 0.8mg/kg IV q12H days -6 to -3
prior to allogeneic PBSC infusion. GVHD prophylaxis included
tacrolimus and mini-methotrexate. GM-CSF (Leukine) 250
mg/m2 SC QD was administered from day 1 until engraftment.
GVAX was administered SC/ID weekly for the ﬁrst three doses,
then q2 weeks for the last three doses starting between day 30 to
45 if there was neutrophil recovery and no grade II-IV acute
GVHD. Tacrolimus was tapered after vaccine completion. Twenty
patients (11 URD, 9 MRD) have been transplanted to date: 14
AML, 4 MDS/RAEB, 2 CML myeloid blast crisis. Median age was
63 (range, 41-71 yrs). Median marrow blast content at SCT was
22% (range, 6-91%). GVAX was successfully generated for all 20
patients. Median vaccine cell dose was 1.0  107 cells (range,
0.1-1.0 107), and median 24-hour GM-CSF secretion by the
vaccine was 8.2 ng/ml/106cells (range 0.4 - 195). Eight patients did
not initiate vaccination due to: poor neutrophil recovery/re-
lapse(4); aGVHD (2); IPS (1); sepsis(1). Two patients were recently
transplanted and have not started vaccination. Among 10 patients
who received GVAX, vaccination was well tolerated. Donor chi-
merism was not adversely affected by vaccination. Six of 10 patients
who started GVAX are alive at a median follow up of 7.5 months
post transplant (range 1-16 mos), and all are in complete remission
(4 AML, 2 MDS-RAEB) between 3 and 16 months after transplant.
Histologic examination of vaccination and leukemia cell DTH sites
revealed signiﬁcant inﬁltration with inﬂammatory cells and eosin-
ophils. These preliminary results suggest GVAX vaccination is safe
and may have anticancer activity in patients with MDS/AML after
allogeneic SCT.
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SHORTER SURVIVAL FOLLOWING HLA-MATCHED SIBLING BONE MAR-
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